Article

Exploring New Treatment Options In HCC

Author(s):

This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.

Date/Time: Tuesday, June 23, 2020 at 8 PM EST

This OncLive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC.

Click here to register today!

The following topics will be discussed:

  • Impact of the COVID pandemic on reentry and reopening
  • Selection of therapy during the pandemic, oral versus IV therapies and immunotherapy
  • Recent approval of atezolizumab + bevacizumab and how this will impact the treatment landscape of HCC

Associate Professor of Clinical Medicine; Medical Director of Clinical Investigations Support Office; Phase I program director, USC Norris Comprehensive Cancer Center, Los Angeles, CA

Amit G. Singal, MD, David Bruton Jr. Professor in Clinical Cancer Research; Associate Professor of Medicine; Medical Director of Liver Tumor Program; Clinical Chief of Hepatology, University of Texas Southwestern, Dallas, TX

Catherine T. Frenette, MD, Director of Gastroenterology, Transplant Hepatology, MD Anderson Cancer Center, La Jolla,CA

Sponsored By:

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD